Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.82 |
| ▸ | HPGD | P15428 | 5/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | RECQL | P46063 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | TNKS | O95271 | 4/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | GLA | P06280 | 2/20 | 0.74 |
| ▸ | THRB | P10828 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | MAOB | P27338 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30777197 | 1.00 | CYP3A4 (0.82) | CYP3A4KDM4EHPGDSMN1; SMN2MAPK1 | |
| 7,3'-Dimethoxyflavone SCHEMBL718068 | 0.90 | KDM4E (1.00) | CYP3A4KDM4EHPGDSMN1; SMN2MAPK1 | |
| 6,3'-Dimethoxyflavone SCHEMBL516389 | 0.89 | KDM4E (0.82) | CYP3A4KDM4EHPGDSMN1; SMN2MAPK1 | |
| 6,3'-Dimethoxyflavone SCHEMBL30894690 | 0.89 | KDM4E (0.82) | CYP3A4KDM4EHPGDSMN1; SMN2MAPK1 | |
| 3',5'-Dimethoxyflavone SCHEMBL29149133 | 0.88 | TNKS (0.78) | CYP3A4KDM4EHPGDSMN1; SMN2MAPK1 | |
| SCHEMBL31238401 | 0.85 | KDM4E (0.85) | CYP3A4KDM4EHPGDSMN1; SMN2MAPK1 | |
| 4'-Methoxyflavone SCHEMBL29573796 | 0.85 | MAOB (1.00) | CYP3A4KDM4EHPGDSMN1; SMN2MAPK1 | |
| 4'-Methoxyflavone SCHEMBL311931 | 0.85 | MAOB (1.00) | CYP3A4KDM4EHPGDSMN1; SMN2MAPK1 | |
| SCHEMBL31238494 | 0.84 | ABCB1 (0.79) | CYP3A4KDM4EHPGDSMN1; SMN2MAPK1 | |
| SCHEMBL4649870 | 0.84 | MAPT (1.00) | CYP3A4KDM4EHPGDSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10952458-B2 | Stevia extract containing selected steviol glycosides as flavor, salty and sweetness profile modifier | PURECIRCLE USA INC (US) | 2021-03-23 | — | — | US | claimed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | claimed |
| US-12011017-B2 | Stevia extract containing selected steviol glycosides as flavor, salty and sweetness profile modifier | PURECIRCLE USA INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11957756-B2 | Stevia extract containing selected steviol glycosides as flavor, salty and sweetness profile modifier | PURECIRCLE SDN BHD (MY) | 2024-04-16 | — | — | US | disclosed |
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-3003058-B2 | STEVIA EXTRACT CONTAINING SELECTED STEVIOL GLYCOSIDES AS FLAVOR, SALTY AND SWEETNESS PROFILE MODIFIER | PURECIRCLE USA INC (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20210186070-A1 | STEVIA EXTRACT CONTAINING SELECTED STEVIOL GLYCOSIDES AS FLAVOR, SALTY AND SWEETNESS PROFILE MODIFIER | PURECIRCLE USA INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210000960-A1 | STEVIA EXTRACT CONTAINING SELECTED STEVIOL GLYCOSIDES AS FLAVOR, SALTY AND SWEETNESS PROFILE MODIFIER | PURECIRCLE SDN BHD (MY) | 2021-01-07 | — | — | US | disclosed |
| EP-3714699-A1 | STEVIA EXTRACT CONTAINING SELECTED STEVIOL GLYCOSIDES AS FLAVOR, SALTY AND SWEETNESS PROFILE MODIFIER | PureCircle USA Inc. (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-1391327-A1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2003057210-A1 | COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030125264-A1 | Methods For Treating Wounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-07-03 | — | — | US | disclosed |
| US-6555523-B1 | Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus | CASCADE ESTATES LTD. (MU) | 2003-04-29 | — | — | US | disclosed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | disclosed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125264-A1 | Methods For Treating Wounds | FGF2, MMP1, FIBP | CYP3A4 3010/4885KDM4E 2309/4885HPGD 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.